Topics

Tumor-Infiltrating Lymphocyte (TIL) Therapy

Cancer Immunotherapy Tumor Microenvironment Cellular Stress Cell Programmed Death

Tumor-infiltrating lymphocyte therapy expands a patient’s own lymphocytes from a resected tumor and returns them after lymphodepleting conditioning. The platform preserves a naturally selected, polyclonal repertoire that may recognize multiple shared and private tumor antigens. Early melanoma studies established durable regressions with TIL-based adoptive therapy, and pooled clinical evidence for lifileucel in advanced melanoma after checkpoint and targeted therapy renewed the field. Unlike CAR-T therapy, TILs do not require one predefined surface antigen; unlike a single TCR product, they can cover multiple peptide–MHC targets. Their advantages are balanced by variable starting material, individualized manufacturing, intensive conditioning, and dependence on intact antigen presentation Regulatory progress has converted decades of individualized academic experience into a more standardized product model, while retaining the biological complexity of each patient’s tumor[1][2][3].

TILs are isolated from tumor fragments, expanded under cytokine support, and selected or enriched for growth and tumor reactivity. Lymphodepletion reduces competing and suppressive cells and increases homeostatic cytokines before infusion, while interleukin-2 can support expansion afterward. Effective clones must traffic back to lesions, recognize peptide–MHC, form cytotoxic synapses, and persist. The harvested population can include bystander, terminally exhausted, and tumor-reactive cells, so cell composition matters. Chronic stimulation, inhibitory receptors, metabolic stress, and loss of tumor antigen presentation can limit function even when large numbers of cells are infused Culture duration is a tradeoff because expansion supplies dose but can reduce clonal diversity, proliferative reserve, and the tissue-homing properties needed after infusion[1][2].

The most established application is advanced melanoma, particularly after progression on immune checkpoint inhibitors, but programs are expanding into cervical, lung, ovarian, head and neck, and other solid tumors. Surgical access to a suitable lesion is required, and manufacturing time can be difficult for rapidly progressive disease. Toxicity arises from lymphodepleting chemotherapy, cytokine support, infection risk, cytopenia, and capillary or organ stress rather than from a synthetic receptor alone. New approaches select neoantigen-reactive clones, use less differentiated cells, add checkpoint resistance, or shorten culture. Centralized production must preserve product identity while accommodating biological variability Response assessment should account for the interval required for manufacturing and conditioning so that outcomes are not attributed only to the infused product[1][3].

Future trials should connect T-cell clonotypes and phenotypes in the infused product with trafficking, persistence, antigen recognition, and clinical response. Rapid assays are needed to distinguish tumor-reactive cells from bystanders before expansion. Nonmyeloablative conditioning and cytokine support should be optimized to reduce toxicity without sacrificing engraftment. Combination with checkpoint blockade or vaccines may sustain useful clones, but timing must avoid redundant or excessive inflammation. TIL therapy demonstrates that a patient’s tumor already contains therapeutic information; the next advance is to capture the most relevant cells, manufacture them reproducibly, and maintain their function after they re-enter the suppressive tissue from which they were isolated A scalable future may combine centralized quality systems with local tumor procurement and rapid digital transfer of manufacturing and immune-monitoring data. Broader adoption will depend on predictable vein-to-vein time, transparent product specifications, and conditioning regimens that centers can deliver safely outside a few expert programs[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
536
HY-B2176 ATP
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.

Source: widespread

Endogenous Metabolite   NOD-like Receptor (NLR)   Interleukin Related   Bacterial  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
178
HY-B0240 Disulfiram
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu2+ increases intracellular ROS levels and induces cuproptosis.
Aldehyde Dehydrogenase (ALDH)   Interleukin Related   Pyroptosis   Apoptosis   Cuproptosis  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
161
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-14519 Methotrexate
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Antifolate   Dihydrofolate reductase (DHFR)   NO Synthase   COX   Interleukin Related  
Breast Cancer   Arthritis   Systemic Lupus Erythematosus   Psoriasis   Lung Fibrosis  
87
HY-L017 Stem Cell Signaling Compound Library
Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy. MCE owns a unique collection of 2,931 compounds that can be used for stem cell regulatory and signaling pathway research.

Signaling Pathway Targeting Libraries

86
HY-L077 Anti-Pancreatic Cancer Compound Library
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 4,336 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Disease Focused Libraries

85
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L080 Targeted Therapy Drug Library
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases. MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

Disease Focused Libraries

84
HY-L151 PROTAC Library
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy. MCE supplies a unique collection of 544 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

Compound Characteristic Classified Libraries

84
HY-L074 Anti-Breast Cancer Compound Library
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Disease Focused Libraries

83
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L171 Anti-Hematopathy Compound Library
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 4,388 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Disease Focused Libraries

83
HY-L178 Radioprotector Library
Radiation sickness is a general term for various types and degrees of damage (or disease) occurring in the human body after exposure to ionizing radiation. Although small amounts of ionizing radiation can also cause the body to produce free radicals and ROS, causing oxidative stress, resulting in DNA damage and chromosomal aberration. Radioprotector are compounds with radiation protection that can be used to prevent/protect non-tumor cells from the harmful effects of radiation. Radioprotective compounds can prevent the damage of radioactive substances to the human body and reduce the clinical symptoms of various radioactive diseases. In addition, radioprotectors can protect normal cells from damage during radiation therapy. The ideal anti-radiation drug should not affect the sensitivity of tumor cells to radiation therapy while protecting normal cells. MCE designs a unique collection of 3,066 radioprotectors. Radioprotector Library is an effective tool for acute Radiation Syndrome, drug combination research with radiation drugs.

Compound Characteristic Classified Libraries

83
HY-L217 Mouse Metabolite Compound Library
Metabolic abnormalities lead to dysfunction of metabolic pathways and the accumulation or lack of metabolites, which are recognized hallmarks of the disease. The metabolite signature is closely related to the disease phenotype and is very useful for predicting the diagnosis and prognosis of the disease as well as monitoring treatment. Metabolites can be used as disease markers for diagnostic therapy. As the classic model of disease experiment in vivo, mice metabolites also play a role in disease diagnosis and mechanism research. MCE provides 330 mouse metabolites that can be used in disease research.

Metabolism Focused Libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-107202 Polyinosinic-polycytidylic acid
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Digestive System Disease   Prostate Cancer   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
73
HY-123606 GSK484
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8+ T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions.
Protein Arginine Deiminase   MHC  
Digestive System Disease   Colitis   Sickle Cell Disease   Cardiomyopathy   Rheumatoid Arthritis  
57
HY-108841 Raleukin
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction.

Species: Human

Interleukin Related  
Metastatic Breast Cancer   SARS-CoV-2 Infection   Rheumatoid Arthritis  
57
HY-B1081A Oxidopamine hydrobromide
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
Dopamine Receptor   Autophagy   Mitophagy   COX   PGE synthase   Interleukin Related   p38 MAPK   Apoptosis   Caspase  
Breast Cancer   Parkinson's Disease  
50
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P1489A OVA Peptide(257-264) TFA
OVA Peptide(257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
25
HY-P1489 OVA Peptide(257-264)
OVA Peptide(257-264) is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
25
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-N0140 Ursolic acid
Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
Autophagy   Endogenous Metabolite  
Prostate Cancer   Leukemia/Lymphoma/Myeloma  
21
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-N0738 Stachydrine hydrochloride
Stachydrine hydrochloride is the major active constituent of Leonurus artemisia, which is a potential therapy for cardiovascular diseases. Stachydrine can inhibit the NF-κB signal pathway. Anti-hypertrophic activities.
NF-κB   Endogenous Metabolite  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity  
9
HY-N0421 Cinobufagin
Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models.

Source: toad

Apoptosis  
Cancer   Neurological, Eye or Ear Disease   Digestive System Disease   Digestive System Inflammation  
9
HY-P9926 Dupilumab
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Breast Cancer   Non-Small Cell Lung Cancer   Staphylococcus Aureus Infection  
9
HY-B2156 Menaquinone-4
Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
Endogenous Metabolite  
Cancer  
8
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-W250978 Ovalbumins
Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment.
Interleukin Related   IFNAR  
Allergic Asthma   Allergic Rhinitis  
6
HY-P9901 Ipilimumab
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.

Species: Human

CTLA-4  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   Metastatic Melanoma  
5
HY-P2336 CCZ01048
CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma.
Melanocortin Receptor  
4
HY-P2336A CCZ01048 TFA
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma.
Melanocortin Receptor  
4
HY-123941 FKBP12 PROTAC dTAG-7
FKBP12 PROTAC dTAG-7 (dTAG-7) is a FKBP12F36V PROTAC degrader. FKBP12 PROTAC dTAG-7 binds FKBP12F36V and CRBN to form a complex, mediating degradation via the ubiquitin-proteasome system. FKBP12 PROTAC dTAG-7 mediates the degradation of FKBP12F36V-tagged nuclear and cytoplasmic proteins, including BRD4, HDAC1, EZH2, MYC, PLK1, KRASG12V, and antigen fusion proteins. FKBP12 PROTAC dTAG-7 enhances MHC class I antigen presentation. FKBP12 PROTAC dTAG-7 is applicable to leukemia-related research.
PROTACs   FKBP   Epigenetic Reader Domain   HDAC   Histone Methyltransferase   c-Myc   Polo-like Kinase (PLK)   Ras   MHC  
Leukemia/Lymphoma/Myeloma  
4
HY-P99575 Tarlatamab
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.

Species: Human

Notch  
Inflammation or Immune System Disease   Respiratory Disease   Small Cell Lung Cancer  
3
HY-14925 Lapaquistat
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy.
Endogenous Metabolite   Drug Metabolite  
Metabolic or Endocrine Disease  
2
HY-N6647 Luteolin-7-rutinoside
Luteolin-7-rutinoside has both anti-arthritic and antifungal activities, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.
Fungal  
Inflammation or Immune System Disease   Fungal Infection   Lung Fibrosis  
2
HY-109520 Glatiramer acetate
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.
MHC  
Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
2
HY-113011 Maltotriose
Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
Endogenous Metabolite  
2
HY-P99931 Epcoritamab
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines.

Species: Human

CD3   CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-122506 Salviolone
Salviolone is a natural diterpenoid derivative that can against melanoma cells. Salviolone exhibits a pleiotropic effect against melanoma by hampering cell cycle progression, STAT3 signaling, and malignant phenotype of A375 melanoma cells.
STAT  
Cancer  
1
HY-P1585A Gp100 (25-33), human TFA
Gp100 (25-33), human TFA (Hgp100 (25-33) (TFA)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human TFA is a 9-amino acid (AA) epitope restricted by MHC class I H-2Db and recognized by the T cells. Gp100 (25-33), human TFA has immunogenicity and induces specific T cells. Gp100 (25-33), human TFA can be used for the cancer research, such as melanoma.
MHC  
1
HY-13912G IWP-2 (GMP)
IWP-2 (GMP) is >IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation.
Wnt  
Cancer  
1
HY-A0070AG Liothyronine (GMP)
Liothyronine (Triiodothyronine) (GMP) is the Liothyronine (HY-A0070A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively.
Thyroid Hormone Receptor  
Cancer   Metabolic or Endocrine Disease  
1
HY-15108G Purmorphamine (GMP)
Purmorphamine (GMP) is Purmorphamine (HY-15108) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM.
Smo  
Cancer   Neurological, Eye or Ear Disease  
1
HY-P1585 Gp100 (25-33), human
Gp100 (25-33), human (Hgp100 (25-33)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human is a 9-amino acid (AA) epitope restricted by MHC class I H-2Db and recognized by the T cells. Gp100 (25-33), human has immunogenicity and induces specific T cells. Gp100 (25-33), human can be used for the cancer research, such as melanoma.
MHC  
Cancer  
1
HY-126855 Cholic acid 7-sulfate
Cholic acid 7-sulfate (7-Sulfocholic acid) is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation.
G protein-coupled Bile Acid Receptor 1   MHC  
Glucose Metabolism   Obesity  
1
HY-P99205 Glembatumumab
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity.

Species: Human

ADC Antibodies  
Lung Cancer   Melanoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
1
HY-P99394 Talquetamab
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.

Species: Human

CD3  
Cancer  
1
HY-P99592 Solitomab
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer.

Species: Human

CD3  
Ovarian Cancer  
1
HY-P99033 Mosunetuzumab
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions.

Species: Human

CD20   CD3  
Cancer Immunology   Non-Hodgkin Lymphoma  
1
HY-P99024 Glofitamab
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).

Species: Human

CD20   CD3  
Cancer   Inflammation or Immune System Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P73591 TLR2 Protein, Human (sf9, His)
TLR2 is a protein that plays a critical role in recognizing and responding to various bacterial and mycobacterial pathogens. TLR2 Protein, Human (sf9, His) is the recombinant human-derived TLR2 protein, expressed by Sf9 insect cells , with C-10*His labeled tag.

Species: Human; Source: Sf9 insect cells

CD Antigens Receptor Proteins T Cell CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins Pattern Recognition Receptors TLR2/CD282 Toll-like Receptor

1
HY-P81134 TLR2 Antibody (YA3547)
TLR2 Antibody (YA3547) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TLR2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

1
HY-W272217R Octacosane (Standard)
Octacosane (Standard) is the analytical standard of Octacosane. This product is intended for research and analytical applications. Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l.
Reference Standards   Endogenous Metabolite   Bacterial  
Cancer   Inflammation or Immune System Disease   Bacterial Infection  
/
HY-77813S Benzyl isothiocyanate-d7
Benzyl isothiocyanate-d7 is the deuterium labeled Benzyl isothiocyanate. Benzyl isothiocyanate is a member of natural isothiocyanates with antimicrobial activity. Benzyl isothiocyanate potent inhibits cell mobility, migration and invasion nature and matrix metalloproteinase-2 (MMP-2) activity of murine melanoma cells.
Isotope-Labeled Compounds   Bacterial   Apoptosis   Antibiotic  
Cancer   Metabolic or Endocrine Disease  
/
HY-W018772S D-Ribose-18O
D-Ribose-18O is the 18O labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-100489S TBHQ-d12
TBHQ-d12 (tert-Butylhydroquinone-d12) is the deuterium labeled TBHQ (HY-100489). TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2. TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma[2].
Isotope-Labeled Compounds   Autophagy   ERK   Ferroptosis   Apoptosis   Keap1-Nrf2  
/
HY-137474 Purpurin 18 methyl ester
Purpurin 18 methyl ester, a chlorophyll-a derivative, is a photosensitizer that can be used in photodynamic therapy (PDT). Purpurin 18 methyl ester has photodynamic activity to induce cancer cell death.

Source: sponge Stelletta clavosa

Photosensitizer  
/
HY-N0421R Cinobufagin (Standard)
Cinobufagin (Standard) is the analytical standard of Cinobufagin. This product is intended for research and analytical applications. Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models.
Reference Standards   Apoptosis  
Cancer   Neurological, Eye or Ear Disease  
/
HY-N0131S1 Stigmasterol-d5-1
Stigmasterol-d5-1 is deuterium labeled Stigmasterol. Stigmasterol is a plant sterol which has been focused on the cholesterol-lowering activity and is valued as an anti-stiffness factor in the therapy of rheumatic diseases.
Isotope-Labeled Compounds   MMP   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-P11424 Cyclo(GRGDSPA)
Cyclo(GRGDSPA) is a cyclic RGD peptide targeting αvβ3 integrin. Cyclo(GRGDSPA) reduces the formation of colonies in mice injected with B16-FE7 melanoma cells. Cyclo(GRGDSPA) can be used for melanoma research.
Integrin  
Melanoma  
/
HY-P992392 JM1-24-3
JM1-24-3 is an anti-MUC18 mouse monoclonal antibody with a Kd value of 1.60e-9 M. JM1-24-3 reduces the phosphorylation levels of p-AKT (Ser473) and p-mTOR (Ser2448) in a time-dependent manner. JM1-24-3 exhibits anticancer activity against melanoma. JM1-24-3 can be used in studies related to metastatic melanoma.

Species: Human

Transmembrane Glycoprotein   Akt   mTOR  
Metastatic Melanoma  
/
HY-15947G Ravoxertinib (GMP)
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.
ERK   c-Myc   Hexokinase   Lactate Dehydrogenase  
Breast Cancer   Ovarian Cancer   Squamous Cell Carcinoma  
/
HY-D3432 WazaGaY-1
WazaGaY-1 is an aza-BODIPY derivative, functions as a NIR-I/NIR-II fluorescent contrast agent. WazaGaY-1 undergoes internalization into tumor cells predominantly via clathrin-coated pits. WazaGaY-1 can be used for the research of glioblastoma, ovarian carcinoma and melanoma (Ex/Em = 685/820 nm).
Fluorescent Dye  
Ovarian Cancer   Cancer Immunology   Immunotherapy for Melanoma   Glioblastoma  
/
HY-DY1092 Chlorin e6 (solution)
Chlorin e6 (solution) (Ce6 (solution)) is a photosensitizer and has strong absorption peaks at wavelength of 402 and 662 nm, as well as exhibiting intense fluorescence at 668 nm. Chlorin e6 has antimicrobial efficacy and anticancer activity. Chlorin e6 induces cell apoptosis via caspase-3 activation and can be used for the research of cancer.
Solvent and concentration: DMSO: 10 mM
The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.
Caspase   PARP   Fluorescent Dye   Apoptosis   Bcl-2 Family  
/
HY-D3141 DR probe
DR probe is a "dual-key-and-lock" fluorescent probe designed based on the Resorufin (HY-123533) scaffold (Ex/Em = 647 nm/663-738 nm). DR probe can be sequentially activated by hydrogen peroxide to form the intermediate SR, which acts as a tyrosinase substrate to trigger a fluorescence turn-on signal. DR probe can distinguish normal melanocytes from melanoma cells. DR probe supports cell imaging and can be applied to mouse melanoma models to achieve melanoma diagnosis with higher accuracy and lower false-positive rates. DR probe is applicable to relevant research on melanoma.
/
HY-N3643 Cryptomeridiol
Cryptomeridiol is a platelet-activating factor (PAF) receptor binding inhibitor. Cryptomeridiol has melanogenesis inhibitory activity in the α-MSH (HY-P0252)-stimulated B16 melanoma cells.
Platelet-activating Factor Receptor (PAFR)  
Cancer  
/
HY-P10542 Dodecapeptide AR71
Dodecapeptide AR71 is an inhibitor of melanoma inhibitory activity (MIA). Dodecapeptide AR71 can reduce cell migration, reduce metastasis formation, and increase immune response. Dodecapeptide AR71 can be used in research on the treatment of malignant melanoma.
Others  
Cancer  
/
HY-D3140 MB-m-borate
MB-m-borate is a double-locked near-infrared fluorescence-activated probe (Ex/Em ≈ 647 nm/684 nm). MB-m-borate undergoes cascade activation by hydrogen peroxide and tyrosinase to release the fluorophore methylene blue, thereby generating a fluorescence activation response. MB-m-borate enables precise detection of melanoma in melanoma cells and mouse models. MB-m-borate can be used for melanoma research.
Fluorescent Dye   Tyrosinase  
Mutant Melanoma  
/
HY-P991406 MK-1248
MK-1248 is a human IgG4 monoclonal antibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research.

Species: Human

TNF Receptor  
Cancer  
/
HY-15150G Bemcentinib (GMP)
Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer.
TAM Receptor  
/
HY-D3185 AlDeSense AM
AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-N10437 6-Acetylnimbandiol
6-Acetylnimbandiol (6-O-Acetylnimbandiol) is a non-cytotoxic tyrosinase inhibitor (IC50=69.85 μM) that effectively inhibits melanin production and MITF expression. 6-Acetylnimbandiol can be used in melanoma research.
Tyrosinase  
Cancer  
/
HY-B2156S1 Menaquinone-4-13C6
Menaquinone-4-13C6 is the 13C-labeled Menaquinone-4. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer  
/
HY-B0150G Nicotinamide (GMP)
Nicotinamide (GMP) (Niacinamide (GMP)) is the GMP level of Nicotinamide (HY-B0150). GMP guidelines are used to produce Nicotinamide (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity.
Endogenous Metabolite   Sirtuin   HBV  
Cancer   Infection  
/
HY-W665456 Fmoc-PNA-U-OH
Fmoc‑PNA‑U‑OH is a peptide nucleic acid monomer that can be used for the synthesis of peptide nucleic acids (PNAs). Fmoc‑PNA‑U‑OH exhibits specific binding to adenine, resistance to enzymatic degradation, and strong hybridization properties. Fmoc‑PNA‑U‑OH can be applied in research fields such as gene diagnosis, molecular biology, and antisense therapy.
Drug Intermediate  
/
HY-P991668 PF-06688992 Antibody
PF-06688992 Antibody is an antibody targeting GD3. PF-06688992 Antibody can be used for the synthesis of the antibody-drug conjugate PF-06688992 (HY-P991668).

Species: Human

ADC Antibodies  
Cancer  
/
HY-P991210 Efzimfotase alfa
Efzimfotase alfa (ALXN-1850) is enzyme replacement therapy agent targeting the deficiency of tissue-nonspecific alkaline phosphatase (TNSALP). Efzimfotase alfa functions by hydrolyzing the substrates of TNSALP, reducing the concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP). Efzimfotase alfa is promising for research of hypophosphatasia (HPP).
Phosphatase  
Blood or Cardio-cerebrovascular Disease  
/
HY-P10656 Ac-DEVDD-TPP
Ac-DEVDD-TPP is a porphyrin derivative that can be converted into D-TPP by caspase-3 cleavage and laser irradiation. The formed porphyrin nanofibers can effectively induce Apoptosis and Pyroptosis. Ac-DEVDD-TPP has antitumor activity.
Apoptosis   Pyroptosis  
Cancer  
/
HY-W040073S Nifurtimox-d4
Nifurtimox-d4 is deuterium labeled Nifurtimox. Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).
Isotope-Labeled Compounds   Parasite   Lactate Dehydrogenase  
Cancer   Infection  
/
HY-10966G SB-590885 (GMP)
SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer.
Raf   Apoptosis  
Colorectal Cancer   Blood Disease  
/
HY-P991186 IMM-20059
IMM-20059 is humanized IgG1 monoclonal antibody targeting EPN1. IMM-20059 in combination with Atezolizumab (HY-P9904) significantly enhances tumor regression in the B16.F10 syngeneic melanoma model.

Species: Human

Others  
Cancer  
/
HY-131921 DL-Glyceraldehyde 3-phosphate diethyl acetal barium
DL-Glyceraldehyde 3-phosphate diethyl acetal barium is an Aspartate Aminotransferase isozyme inhibitor.
Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-W708886 Methyl-d3 tetradecanoate
Methyl-d3 tetradecanoate is the deuterium labeled Methyl myristate (HY-W004288). Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma.
Isotope-Labeled Compounds   Drug Derivative  
/
HY-P1160A Bay 55-9837 TFA
Bay 55-9837 TFA is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes.
GCGR  
Metabolic or Endocrine Disease  
/
HY-N11108 Gochnatiolide A
Gochnatiolide A is a dimeric sesquiterpene that can be found in Ainsliaea henryi. Gochnatiolide A exhibits antiproliferative activity against the kidney, melanoma, ovarian-resistant and glioma cell lines.
Others  
Cancer  
/
HY-P992475 Tecnemab K1
Tecnemab K1 is an anti-Melanoma monoclonal antibody. Tecnemab K1 accumulates in metastatic lesions of malignant melanoma and some benign lesions. When radiolabeled, Tecnemab K1 can serve as a radiotracer for malignant melanoma research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species: Human

Radionuclide-Drug Conjugates (RDCs)  
Metastatic Melanoma  
/
HY-P3996 Properdistatin
Properdistatin is a peptide derived from the thrombospondin 1 (TSP-1) domain of properdin. Properdistatin inhibits angiogenesis and improves vascular function. Properdistatin has the potential for the research of melanoma.
Others  
Cancer  
/
HY-P992335 COM503
COM503 is a high-affinity anti-IL18BP human monoclonal antibody with a Kd value of 0.291 pM. COM503 binds to IL18BP, blocks the IL18BP:IL18 interaction, displaces IL18 from preformed complexes, and enhances the activation and function of T cells and NK cells. COM503 induces anti-tumor effects by relieving the activity inhibition of endogenous IL18 in the tumor microenvironment. COM503 can be used for cancer research. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

Interleukin Related  
Cancer  
/
HY-P992511 CS2009
CS2009 is a trispecific antibody targeting PD-1, CTLA-4 and VEGFA. CS2009 blocks the interactions of PD-1/PD-L1, CTLA-4/CD80 and VEGFA/VEGFR2, mediates checkpoint inhibition, and suppresses tumor angiogenesis. CS2009 reactivates PD-1/CTLA-4 double-positive tumor-infiltrating T lymphocytes, induces T cell activation, enhances tumor growth inhibition, promotes vascular normalization, improves T lymphocyte infiltration, and converts the immunosuppressive tumor microenvironment into an immunocompetent one. CS2009 can be used for the research of various advanced solid tumors.

Species: Human

PD-1/PD-L1   CTLA-4   VEGFR  
Cancer  
/
HY-N7587 Chlorophorin
Chlorophorin is a inhibitor of Melanocortin Receptor. Chlorophorin reduces tyrosinase activity and inhibits a-melanocyte-stimulating hormone-induced melanin production in B16F10 melanoma cells.
Melanocortin Receptor  
Metabolic or Endocrine Disease  
/
HY-N16394 4-Hydroxyscytalone
4-Hydroxyscytalone (Compound 3) is a microbial secondary metabolite. 4-Hydroxyscytalone can be isolated from the oak fungus Diplodia corticola. 4-Hydroxyscytalone has toxicity against Artemia salina with a LC50 of 90.6 μ/mL, but no significant antifungal activity. 4-Hydroxyscytalone can be used for cancer therapy research.

Source: Xylaria polymorpha

Endogenous Metabolite  
Cancer  
/
HY-P10562 BMV Gag-(7−25)
BMV Gag-(7 25) is an arginine-rich peptide with cell-penetrating ability. BMV Gag-(7 25) can be used in drug delivery and gene therapy research.
TMV  
/
HY-W018772S6 D-Ribose-d
D-Ribose-d is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gly
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-172351B PEG10000-bis-amine
PEG10000-bis-amine is a bisamine-terminated polyethylene glycol that serves as a key starting material for the preparation of cholesterol-conjugated polyethylene glycol derivatives. After radioiodination modification, PEG10000-bis-amine significantly prolongs plasma retention time and exhibits enhanced tumor accumulation in a subcutaneous melanoma mouse model. PEG10000-bis-amine has important application value in studies of tumor-targeted delivery and drug modification.
Biochemical Assay Reagents  
Cancer  
/
HY-P992361 HB0030
HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3+ Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors.

Species: Human

Transmembrane Glycoprotein  
Breast Cancer   Colorectal Cancer   Bladder Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer  
/
HY-P10374 Pep42
Pep42, a cyclic peptide ligand of GPR78, internalizes selectively into highly metastatic human melanoma cells through a receptor-mediated process.
Others  
/
HY-P11280 PRAME peptide (425-433)
PRAME peptide (425-433) is a peptide corresponding to amino acids 425-433 of PRAME (preferentially expressed antigen) in melanoma. PRAME peptide (425-433) can be used to stimulate human PRAME-specific CD8+ T cells.
Others  
Cancer  
/
HY-N0610S2 Cinnamic acid-d7
Cinnamic acid-d7 (3-Phenylacrylic acid-d7) is the deuterium labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
Isotope-Labeled Compounds   Endogenous Metabolite   Environmental Pollutants  
Cancer  
/
HY-B0078S Dacarbazine-d6
Dacarbazine-d6 is the deuterium labeled Dacarbazine. Dacarbazine(DTIC-Dome; DTIC) is an antineoplastic agent. It has significant activity against melanomas.
Nucleoside Antimetabolite/Analog   Apoptosis  
Cancer  
/
HY-P991677 Efmirenpase alfa
Efmirenpase alfa is an Fc-ENPP1 fusion protein (human IgG1 Fc domain linked to a modified human ENPP1). Efmirenpase alfa has prolonged half-life and enhanced receptor affinity compared with native human ENPP1. Efmirenpase alfa can be used as an enzyme replacement therapy for ENPP1 deficiency such as arterial calcification and hypophosphatemic rickets research.

Species: Human

Phosphodiesterase (PDE)  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-159846S Luvometinib-d
Luvometinib-d (FCN-159-d) is the deuterated-labeled Luvometinib (HY-159846). Luvometinib is an orally potent MEK1/2 inhibitor. Luvometinib selectively blocks the MAPK signaling pathway by forming a ternary complex with MEKase and ATP, thereby reducing the phosphorylation level of ERK. Luvometinib induces cell cycle arrest and apoptosis, and inhibits cancer cell proliferation. Luvometinib can be used in relevant research on various solid tumors including melanoma, non-small cell lung cancer, colon cancer, and acute myeloid leukemia.
Isotope-Labeled Compounds   MEK   p38 MAPK   Apoptosis  
Cancer  
/
HY-P99760 Nurulimab
Nurulimab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) human monoclonal antibody. Nurulimab binds to CTLA-4 and blocks its interaction with ligands, stimulating T-cell proliferation, cytokine production, and inducing an antitumor immune response. Nurulimab can be used for the research of unresectable or metastatic melanoma and advanced cutaneous melanoma.

Species: Human

CTLA-4  
Melanoma   Cancer Immunology  
/
HY-W004288S Methyl tetradecanoate-d27
Methyl tetradecanoate-d27 is the deuterium labeled Methyl myristate. Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma.
Isotope-Labeled Compounds   Drug Derivative  
Cancer  
/
HY-W018772S14 D-Ribose-d5
D-Ribose-d5 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-106187B MART-1 (27-35) (human) TFA
MART-1 (27-35) (human) TFA is the amino acid fragment spanning positions 27 to 35 of the MART-1 protein, and it represents an immunogenic epitope recognizable by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs). MART-1 (27-35) (human) TFA can be used in studies related to melanoma.
Biochemical Assay Reagents  
Melanoma  
/
HY-N0610AS2 Cinnamic acid-13C3
Cinnamic acid-13C3 (3-Phenylacrylic acid-13C3) is the 13C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
Isotope-Labeled Compounds   Endogenous Metabolite  
/
HY-NP134 Flagellin from S. typhimurium
Flagellin from S. typhimurium is a potent TLR5 agonist. Flagellin from S. typhimurium activates immune cells and inhibits the activity of melanoma cells. Flagellin from S. typhimurium activates the NF-κB pathway dependent on the TLR5/MyD88/TRAF6 signaling axis in cells. Flagellin from S. typhimurium induces a proinflammatory response in the primary chicken hepatocyte-nonparenchymal cell co-culture system by promoting IL-8 production, inhibiting IL-10 production, and increasing the IFN-γ/IL-10 ratio. Flagellin from S. typhimurium can be used for research on melanoma and inflammatory diseases.
Toll-like Receptor (TLR)   MyD88   NF-κB   Interleukin Related   IFNAR  
Inflammation or Immune System Disease   Melanoma  
/
HY-P991689 Girancitug
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research.

Species: Human

VEGFR  
Cancer  
/
HY-P11280A PRAME peptide (425-433) acetate
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma.
Melanocortin Receptor  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Lung Squamous Cell Carcinoma   Squamous Cell Carcinoma  
/
HY-15682G TTNPB (GMP)
TTNPB (Ro 13-7410) (GMP) is TTNPB (HY-15682) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TTNPB is a highly potent retinoic acid receptor (RAR) agonist.
RAR/RXR  
Cancer  
/
HY-P10239 Tyr3-Octreotate
Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC50 value of 1.3 nM against sst2 when labeled with [111In-DTPA], and an IC50 value of 1.6 nM against sst2 when labeled with [90Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with 177Lu or 90Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors.
Somatostatin Receptor   Radionuclide-Drug Conjugates (RDCs)  
Pancreatic Cancer  
/
HY-P991781 Anti-Mouse CXCR6 Antibody (Cx6Mab-1)
Anti-Mouse CXCR6 Antibody (Cx6Mab-1) is a monoclonal antibody targeting mouse CXC chemokine receptor 6 (mCXCR6), with a KD of 1.7 nM against CHO/mCXCR6-overexpressing cells. Anti-Mouse CXCR6 Antibody (Cx6Mab-1) binds to the N-terminal domain epitope of mCXCR6 containing Ser8, Ala9, Leu10, Tyr11, Gly13 and His14, and interacts with both overexpressed and endogenous forms of the receptor. Anti-Mouse CXCR6 Antibody (Cx6Mab-1) can be used in studies related to mouse lymphoma.

Species: Mouse

CXCR  
Leukemia/Lymphoma/Myeloma  
/
HY-W018772S10 D-Ribose-5,5-C-d2
D-Ribose-d2 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-W018772S1 D-Ribose-13C
D-Ribose-13C is the 13C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-106187 MART-1 (27-35) (human)
MART-1 (27-35) (human) is the amino acid fragment spanning positions 27 to 35 of the MART-1 protein, and it represents an immunogenic epitope recognizable by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs). MART-1 (27-35) (human) can be used in studies related to melanoma.
Biochemical Assay Reagents  
Cancer  
/
HY-W272217 Octacosane
Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l.
Endogenous Metabolite   Bacterial  
Inflammation or Immune System Disease  
/
HY-17447AG Tranylcypromine hydrochloride (GMP)
Tranylcypromine (SKF 385) hydrochloride (GMP) is Tranylcypromine hydrochloride (HY-17447A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tranylcypromine hydrochloride is a potent monoamine oxidase (MAO) inhibitor.
Monoamine Oxidase  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P99608 Exbivirumab
Exbivirumab is a monoclonal antibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant.

Species: Virus

HBV  
Infection  
/
HY-118924 IR-825
IR-825 is a near infrared fluorescent dye.the end of IR-825 has carboxyl COOH active group, and can participate in the reaction to connect other molecules. IR-825 can be widely used in tumor photothermal study..
Fluorescent Dye  
Cancer  
/
HY-P3813 Tyrosinase (206-214), human
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL).
Tyrosinase  
Cancer   Inflammation or Immune System Disease  
/
HY-W272217S Octacosane-d58
Octacosane-d58 is the deuterium labeled Octacosane. Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l.
Bacterial   Endogenous Metabolite  
Cancer   Bacterial Infection  
/
HY-P991179 MK-4166
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes.

Species: Human

TNF Receptor  
Cancer  
/
HY-P991911 PLT012
PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatory T cells (Tregs) and CD8+ tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8+ T cell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted T cells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research.

Species: Human

Scavenger Receptor Class B type I (SR-BI）  
Colorectal Cancer   Hepatitis B Virus Related Hepatocellular Carcinoma  
/
HY-P99807 Prolgolimab
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma.

Species: Human

PD-1/PD-L1  
Lung Cancer  
/
HY-135119 Salmeterol-d3
Salmeterol-d3 is a deuterium labeled Salmeterol. Salmeterol is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.
Adrenergic Receptor  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-D1299 meso-CF3-BODIPY 2
meso-CF3-BODIPY 2 (CF3-substituted Tetramethyl BODIPY) is a fluorescent dye with the absorption wavelength (λabs) of 553 nm and emission wavelength (λem) of 622 nm. meso-CF3-BODIPY 2 can be used in labeling reagents and photodynamic therapy.
Fluorescent Dye  
Cancer  
/
HY-N2600 Kuwanon H
Kuwanon H is a selective non-peptide bombesin receptor antagonist and platelet activation inhibitor. Kuwanon H also acts as a specific antagonist of GRP-preferring receptors, with a Ki value of 290 nM for mouse GRP-R and 6500 nM for rat NMB-R. Kuwanon H inhibits the phosphorylation of AKT, mTOR, ERK, cPLA2 and p38, and upregulates TRIB3. It induces endoplasmic reticulum stress, apoptosis and autophagosome formation. Kuwanon H blocks calcium mobilization, mitogenic signaling, DNA synthesis, dense granule secretion, thromboxane A2 generation and integrin αIIb/β3 activity. It inhibits collagen-induced platelet aggregation and fibronectin adhesion, and delays clot retraction. Kuwanon H inhibits melanoma cell growth in vitro and in vivo, and enhances the sensitivity of melanoma cells to CDDP. It can be used in research related to melanoma, small cell lung cancer and thrombosis.
Bombesin Receptor   Akt   mTOR   ERK   p38 MAPK   Apoptosis   Autophagy  
Melanoma   Blood Disease   Small Cell Lung Cancer  
/
HY-W018772S12 D-Ribose-d6
D-Ribose-d6 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-W008818 4'-Aminoacetophenone
4'-Aminoacetophenone (p-Aminoacetophenone) is an intermediate that can be used for the synthesis of other active compounds, such as antitumor agents.
Drug Intermediate  
/
HY-B2156R Menaquinone-4 (Standard)
Menaquinone-4 (Standard) is the analytical standard of Menaquinone-4. This product is intended for research and analytical applications. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
Reference Standards   Endogenous Metabolite  
Cancer  
/
HY-P99202 Vibostolimab
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research.

Species: Human

Transmembrane Glycoprotein  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-W001939 4-Acetylbenzoic acid
4-Acetylbenzoic acid is a Zn(II) complex. 4-Acetylbenzoic acid is a derivative of benzoic acid that is commonly used in chemical synthesis. 4-Acetylbenzoic acid has an IC50 of 331.3 μM in murine L929 fibroblasts and an IC50 of 176 μM in metastatic melanoma B16 F10 cell lines.
Biochemical Assay Reagents  
Cancer  
/
HY-P990690 Volrustomig
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1+ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1+ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer.

Species: Human

PD-1/PD-L1   CTLA-4  
Gastric Cancer   Liver Cancer   Cervical Cancer   Non-Small Cell Lung Cancer  
/
HY-P990569 CM-24
CM-24 (MK-6018) is a highly selective humanized monoclonal antibody targeting CEACAM1/CD66a. CM-24 binds to the N-terminal domain of CEACAM1, blocks the CEACAM1-CEACAM1 interaction, relieves the co-inhibitory effect on CEACAM1-positive lymphocytes, and enhances the cytotoxic activity of TIL, LAK and NK cells against CEACAM1-positive tumor cells. CM-24 can be used in studies related to tumor immunology, tumor metastasis and thrombosis. For the isotype control of CM-24, refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-W020958 Ru(acac)3
Ru (acac) 3 (Tris (acetylacetonato) ruthenium (III)) is a caspase-3 activator and Apoptosis inducer. Ru (acac) 3 exerts growth inhibitory effects on various cell lines in vitro by inhibiting DNA/RNA synthesis and inducing mild reversible S-phase cell cycle arrest. Ru (acac) 3 is commonly used in research related to ovarian cancer, osteosarcoma, cervical cancer, melanoma, and other fields.
Caspase   Apoptosis  
Cervical Cancer   Ovarian Cancer  
/
HY-N0610AS Cinnamic acid-d6
Cinnamic acid-d6 is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
Endogenous Metabolite  
/
HY-13257G Thiazovivin (GMP)
Thiazovivin (GMP) is Thiazovivin (HY-13257) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Thiazovivin is a potent ROCK inhibitor.
ROCK  
Cancer  
/
HY-10432G A 83-01 (GMP)
A 83-01 (GMP) is A 83-01 (HY-10432) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. A 83-01 is a potent ALK4/5/7 inhibitor.
Anaplastic lymphoma kinase (ALK)  
Cancer  
/
HY-N0140R Ursolic acid (Standard)
Ursolic acid (Standard) is the analytical standard of Ursolic acid. This product is intended for research and analytical applications. Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
Reference Standards   Autophagy   Endogenous Metabolite  
Cancer  
/
HY-13740G Resiquimod (GMP)
Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages.
Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease  
/
HY-P1827 mTRP-2 (180-188)
mTRP-2 (180-188) is an MHC class I-restricted tumor-associated antigenic peptide derived from mouse tyrosinase-related protein 2 (TRP-2). mTRP-2 (180-188) binds to HLA-A*0201 with an ID50 of 36 nM. mTRP-2 (180-188) can be presented by H-2Kb molecules and activate TRP-2-specific cytotoxic T lymphocytes (CTL). mTRP-2 (180-188) induces immune responses against B16 melanoma by promoting antigen-specific T cell proliferation, cytokine release, and CTL-mediated tumor cell killing. mTRP-2 (180-188) can be used in studies related to melanoma, glioma, and tumor immunology.
Tyrosinase   MHC  
Melanoma  
/
HY-13027G DAPT (GMP)
DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active γ-secretase inhibitor.
γ-secretase  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P99049 Sotigalimab
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma.

Species: Human

TNF Receptor  
Inflammation or Immune System Disease   Metastatic Pancreatic Cancer   Metastatic Melanoma  
/
HY-159069 Zymosan (ZM), 95%
Zymosan (ZM), 95% is a yeast cell wall-derived carbohydrate-rich preparation and immunomodulator. Zymosan (ZM), 95% binds to and activates TLR-2, TLR-4, and Dectin-1 receptor to trigger downstream signaling pathways. Zymosan (ZM), 95% upregulates TLR-2, TLR-4, and TNF-α mRNA expression, increases serum TNF-α levels, and stimulates splenocyte number and viability in mice. Zymosan (ZM), 95% attenuates melanoma growth progression, modulates macrophage marker gene expression, and mediates phagocytosis, ROS generation, and cytokine production. Zymosan (ZM), 95% reduces Connexin 43 protein and mRNA levels, inhibits gap junctional intercellular communication, and induces proinflammatory factor production in human corneal cells. Zymosan (ZM), 95% induces peritoneal inflammation in mice, functions as a drug carrier, and supports fibroblast cell attachment in hydrogel formulations. Zymosan (ZM), 95% can be used for the research of melanoma, tumors, fungal keratitis, ocular surface inflammatory disorders, and peritoneal inflammation.
C-type Lectin-like Receptors (CTLRs)   Toll-like Receptor (TLR)   TNF Receptor   Connexin  
Cancer   Fungal Infection  
/
HY-108786 Asfotase alfa
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 / knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP).

Species: Human

Phosphatase  
Metabolic or Endocrine Disease  
/
HY-P1160 Bay 55-9837
Bay 55-9837 is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes.
GCGR  
Metabolic or Endocrine Disease  
/
HY-P3333 KSPWFTTL
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-19204 Zinc phthalocyanine
Zinc phthalocyanine (ZnPc) is commonly applied in industry (catalysts, photoconductors) and biomedical (photodynamic therapy, PDT). Zinc phthalocyanine can be used to photooxidise cyclohexane and is promising for research of solar-cell applications.
Ligands for Target Protein for PROTAC   Reactive Oxygen Species (ROS)   Apoptosis   Caspase  
Cancer  
/
HY-P1587 IRBP (1-20), human
IRBP (1-20), human contains a major epitope for the H-2b haplotype. IRBP (1-20), human induces experimental autoimmune uveoretinitis (EAU) in H-2b mice.
MHC  
Inflammation or Immune System Disease  
/
HY-P4193 AH1
AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8+ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I Ld molecule. AH1 can be used for the research of colorectal carcinoma.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-108775A Sodium thiosulfate (99%, water≤1.0%)
Sodium thiosulfate (Sodium hyposulfite) is an antioxidant. Sodium thiosulfate inhibits the expression of p-GSK-3β and β-catenin proteins, reduces IL-1β, COX-2, and Iba-1, and inhibits NFκB activation. Sodium thiosulfate promotes angiogenesis, inhibits inflammation, and improves acute lung injury. Sodium thiosulfate also exhibits anti-cancer activity against melanoma. Sodium thiosulfate also exerts renal protective effects. Sodium thiosulfate can be used in the research of osteoarthritis, brain inflammation, cancer (such as breast cancer, melanoma), and kidney disease.
COX   β-catenin   NF-κB   Interleukin Related   GSK-3  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease   Breast Cancer   Melanoma   Antioxidant Agent   Osteoarthritis  
/
HY-101952G Prostaglandin E2 (GMP)
Prostaglandin E2 (GMP) is Prostaglandin E2 (HY-101952) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Prostaglandin E2, an inflammatory mediator, is a endogenous hormone-like substance that participate in a wide range of body functions.
Endogenous Metabolite  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P991028 Surovatamig
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

Species: Human

CD3   CD19   Interleukin Related   TNF Receptor   IFNAR  
Non-Hodgkin Lymphoma  
/
HY-P9918 Tremelimumab
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

Species: Human

CTLA-4  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P991015 Pasritamig
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P9954 Catumaxomab
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers.

Species: Human

CD3  
Gastric Cancer   Ovarian Cancer  
/
HY-P990688 Xaluritamig
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P99392 Teclistamab
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).

Species: Human

CD3  
Cancer  
/
HY-P75612 CD146/MCAM Protein, Human (HEK293, His)
The CD146/MCAM protein is critical for maintaining endothelial monolayer integrity and cell adhesion in vascular tissue. Its expression promotes the interaction of melanoma cells with the vasculature and may contribute to tumor spread through the bloodstream. CD146/MCAM Protein, Human (HEK293, His) is the recombinant human-derived CD146/MCAM protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) MCAM/CD146 Immunoglobulin-like Cell Adhesion Molecules

/
HY-P75611 CD146/MCAM Protein, Human (HEK293, Fc)
The CD146/MCAM protein is critical for maintaining endothelial monolayer integrity and cell adhesion in vascular tissue. Its expression promotes the interaction of melanoma cells with the vasculature and may contribute to tumor spread through the bloodstream. CD146/MCAM Protein, Human (HEK293, Fc) is the recombinant human-derived CD146/MCAM protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) MCAM/CD146 Immunoglobulin-like Cell Adhesion Molecules

/
HY-P72605 IgG2 Fc Protein, Human (V161M, S257A, HEK293)
The IgG2 Fc protein is the constant region of the immunoglobulin heavy chain and acts as an antigen receptor, triggering the expansion and differentiation of B lymphocytes into immunoglobulin-secreting plasma cells.IgG2 Fc Protein, Human (V161M, S257A, HEK293) is the recombinant human-derived IgG2 Fc protein, expressed by HEK293 , with tag free.

Species: Human; Source: HEK293

Fc Receptors Immunoglobulin Fc Region IgG2

/
HY-P73590Y TLR2 Protein, Mouse (sf9, His, solution)
The TLR2 protein cooperates with LY96 to initiate an immune response against bacterial lipoproteins and cell wall components.It cooperates with TLR1 or TLR6 to activate NF-kappa-B, induce cytokine secretion, and form activation clusters such as TLR2:TLR6:CD14:CD36.TLR2 Protein, Mouse (sf9, His, solution) is the recombinant mouse-derived TLR2 protein, expressed by Sf9 insect cells , with C-10*His labeled tag.

Species: Mouse; Source: Sf9 insect cells

CD Antigens T Cell CD Proteins TLR2/CD282

/
HY-P72258 Melanoma antigen preferentially/PRAME, Human (His)
PRAME is located in the CRL2 E3 ubiquitin-protein ligase complex and directs ubiquitination and degradation, specifically targeting the truncated MSRB1/SEPX1 selenoprotein.It is recruited to active promoter regions and is involved in chromatin regulation.Melanoma antigen preferentially/PRAME, Human (His) is the recombinant human-derived Melanoma antigen preferentially/PRAME, expressed by E.coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

CD Antigens

/
HY-P76201 CD146/MCAM Protein, Mouse (HEK293, His)
The CD146/MCAM protein is a multifunctional adhesion regulator that plays a crucial role in maintaining endothelial monolayer adhesion in vascular tissue. Its expression is associated with promoting interactions between melanoma cells and vascular components, potentially enhancing hematogenous spread of tumors. CD146/MCAM Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD146/MCAM protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens Receptor Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) MCAM/CD146 Immunoglobulin-like Cell Adhesion Molecules

/
HY-P73589 TLR2 Protein, Rat (sf9, His)
TLR2 Protein cooperates with LY96 to initiate innate immune response against bacterial lipoproteins and microbial cell wall components. It also cooperates with TLR1 or TLR6 for the immune response to bacterial lipoproteins or lipopeptides. This involves NF-kappa-B activation, cytokine secretion, and induction of inflammatory response via MYD88 and TRAF6 signaling pathways. TLR2 Protein, Rat (sf9, His) is the recombinant rat-derived TLR2 protein, expressed by Sf9 insect cells , with C-His labeled tag.

Species: Rat; Source: Sf9 insect cells

CD Antigens Receptor Proteins T Cell CD Proteins Monocyte CD Proteins Epithelial cell CD Proteins Pattern Recognition Receptors TLR2/CD282 Toll-like Receptor

/
HY-P705219 IgG2 Fc Protein, Human (Biotinylated, HEK293, Avi)

Species: Human; Source: HEK293

Fc Receptors Biotinylated Proteins Immunoglobulin Fc Region

/
HY-P70846A MIA Protein, Human (N-His)
MIA proteins exhibit significant growth inhibitory effects on melanoma cells in vitro, extending their effects to various neuroectodermal tumors such as gliomas. In addition to playing an inhibitory role in cell growth, MIA proteins are also involved in molecular interactions, interacting with FASLG and TMIGD2. MIA Protein, Human (N-His) is the recombinant human-derived MIA protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Cytokines and Growth Factors

/
HY-P70846 MIA Protein, Human (His)
MIA proteins exhibit significant growth inhibitory effects on melanoma cells in vitro, extending their effects to various neuroectodermal tumors such as gliomas. In addition to playing an inhibitory role in cell growth, MIA proteins are also involved in molecular interactions, interacting with FASLG and TMIGD2. MIA Protein, Human (His) is the recombinant human-derived MIA protein, expressed by E. coli , with C-6*His labeled tag.

Species: Human; Source: E. coli

Cytokines and Growth Factors

/
HY-P75613 CD146/MCAM Protein, Human (Biotinylated, HEK293, His)
The CD146/MCAM protein is critical for maintaining endothelial monolayer integrity and cell adhesion in vascular tissue. Its expression promotes the interaction of melanoma cells with the vasculature and may contribute to tumor spread through the bloodstream. CD146/MCAM Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived CD146/MCAM protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) MCAM/CD146 Immunoglobulin-like Cell Adhesion Molecules

/
HY-P78582 CD146/MCAM Protein, Cynomolgus (HEK293, His)
The CD146/MCAM protein is a multifunctional adhesion regulator that plays a crucial role in maintaining endothelial monolayer adhesion in vascular tissue. Its expression is associated with promoting interactions between melanoma cells and vascular components, potentially enhancing hematogenous spread of tumors. CD146/MCAM Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD146/MCAM protein, expressed by HEK293 , with C-His labeled tag. The total length of CD146/MCAM Protein, Cynomolgus (HEK293, His) is 536 a.a., with molecular weight of 80-110 kDa.

Species: Cynomolgus; Source: HEK293

Receptor Proteins Cell Adhesion Molecules (CAMs) Immunoglobulin-like Cell Adhesion Molecules

/
HY-P702186 AIM2 Protein, Human
AIM2 protein is a key sensor in the AIM2 inflammasome, which can activate the inflammasome in response to cytoplasmic dsDNA, thereby inducing pyroptosis. This complex is triggered by pathogens or injury signals and plays a critical role in innate immunity and inflammation. AIM2 Protein, Human is the recombinant human-derived AIM2 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Receptor Proteins Pattern Recognition Receptors AIM2-like receptors Absent In Melanoma 2 (AIM2)

/
HY-P702187 AIM2 Protein, Human (His)
AIM2 protein is a key sensor in the AIM2 inflammasome, which can activate the inflammasome in response to cytoplasmic dsDNA, thereby inducing pyroptosis. This complex is triggered by pathogens or injury signals and plays a critical role in innate immunity and inflammation. AIM2 Protein, Human (His) is the recombinant human-derived AIM2 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Receptor Proteins Pattern Recognition Receptors AIM2-like receptors Absent In Melanoma 2 (AIM2)

/
HY-P704090 IgG2 Fc Protein, Human (HEK293)
The IgG2 Fc protein is the constant region of the immunoglobulin heavy chain and acts as an antigen receptor, triggering the expansion and differentiation of B lymphocytes into immunoglobulin-secreting plasma cells. IgG2 Fc Protein, Human (HEK293) is the recombinant human-derived IgG2 Fc protein, expressed by HEK293, with tag free.

Species: Human; Source: HEK293

Fc Receptors Immunoglobulin Fc Region

/
HY-P85933 Melanoma gp100 Antibody (YA5625)
Melanoma gp100 Antibody (YA5625) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Melanoma gp100.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-P82187 Toll-Like Receptor 2 Antibody (YA1932)
Toll-Like Receptor 2 Antibody (YA1932) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Toll-Like Receptor 2.

Host: Rabbit; Reactivity: Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80595 CD146 Antibody (YA544)
CD146 Antibody (YA544) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD146.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83520 Toll-Like Receptor 5 Antibody (YA3265)
Toll-Like Receptor 5 Antibody (YA3265) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Toll-Like Receptor 5.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83084 Melanoma gp100 Antibody (YA2829)
Melanoma gp100 Antibody (YA2829) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Melanoma gp100.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85885 CD63 Antibody (YA5577)
CD63 Antibody (YA5577) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD63.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P810775 Toll-like receptor 5 Antibody (YA10018)
Toll-like receptor 5 Antibody (YA10018) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to Toll-like receptor 5.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84586 CD281 Antibody (YA4283)
CD281 Antibody (YA4283) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD281.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P80595A CD146 Antibody (YA544)(PBS only)
CD146 Antibody (YA544) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD146.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P811373 GSDMC Antibody
GSDMC Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to GSDMC.

Host: Rabbit; Reactivity: Human

Polyclonal Antibodies Primary Antibodies

/
HY-P82187A Toll-Like Receptor 2 Antibody (YA1932)(PBS only)
Toll-Like Receptor 2 Antibody (YA1932) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Toll-Like Receptor 2.

Host: Rabbit; Reactivity: Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84586A CD281 Antibody (YA4283)(PBS only)
CD281 Antibody (YA4283) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD281.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P85790 CD146 Antibody (YA5482)
CD146 Antibody (YA5482) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD146.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P85885A CD63 Antibody (YA5577)(PBS only)
CD63 Antibody (YA5577)(PBS only) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD63.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86057 Melanoma gp100 Antibody (YA5749)
Melanoma gp100 Antibody (YA5749) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Melanoma gp100.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-P86410 CD146 Antibody (YA6102)
CD146 Antibody (YA6102) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD146.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86659 TLR2 Antibody (YA6351)
TLR2 Antibody (YA6351) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TLR2.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/

Keywords

tumor-infiltrating lymphocytes | TIL therapy | lifileucel | adoptive cell therapy | melanoma | lymphodepletion